scholarly journals Beyond Dual Bronchodilation – Triple Therapy, When and Why

2022 ◽  
Vol Volume 17 ◽  
pp. 165-180
Author(s):  
Mario Cazzola ◽  
Paola Rogliani ◽  
Rossella Laitano ◽  
Luigino Calzetta ◽  
Maria Gabriella Matera
Keyword(s):  
Triple Therapy ◽  
Dual Bronchodilation

scholarly journals Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

2018 ◽  
Vol Volume 13 ◽  
pp. 2557-2568 ◽  
Author(s):  
Roland Buhl ◽  
Carl-Peter Criée ◽  
Peter Kardos ◽  
Claus Vogelmeier ◽  
Konstantinos Kostikas ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Real Life ◽  
Dual Bronchodilation

Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD

2018 ◽  
Author(s):  
Jaco Voorham ◽  
Marjan Kerkhof ◽  
Mario Scuri ◽  
Stefano Vezzoli ◽  
Ilaria Valente ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Real World ◽  
Dual Bronchodilation

scholarly journals PRS5 Dual Bronchodilation With Indacaterol and Tiotropium in Combination Versus Triple Therapy, Fixed-Dose Combinations, and Monotherapy in COPD – a Network Meta-Analysis of FEV1

2012 ◽  
Vol 15 (7) ◽  
pp. A560 ◽  
Author(s):  
M. Kraemer ◽  
A. Ellis ◽  
M. Baldwin ◽  
J.P. Jansen ◽  
G. Capkun-Niggli ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Meta Analysis ◽  
Fixed Dose ◽  
Dual Bronchodilation

Dual bronchodilation vs triple therapy in the real-life DACCORD study

2018 ◽  
Author(s):  
Carl-Peter Criee ◽  
Peter Kardos ◽  
Heinrich Worth ◽  
Nadine Lossi ◽  
Konstantinos Kostikas ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Real Life ◽  
The Real ◽  
Dual Bronchodilation

scholarly journals Comparative effectiveness of triple therapy versus dual bronchodilation in COPD

2019 ◽  
Vol 5 (3) ◽  
pp. 00106-2019 ◽  
Author(s):  
Jaco Voorham ◽  
Massimo Corradi ◽  
Alberto Papi ◽  
Claus F. Vogelmeier ◽  
Dave Singh ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Triple Therapy ◽  
Real Life ◽  
Blood Eosinophil ◽  
Exacerbation Rate ◽  
Historical Cohort ◽  
Respiratory Event ◽  
Dual Bronchodilation ◽  
Exacerbation Risk ◽  
Long Acting

This real-world study compared the effectiveness of triple therapy (TT; long-acting muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled corticosteroids (ICSs)) versus dual bronchodilation (DB; LAMAs/LABAs) among patients with frequently exacerbating COPD. A matched historical cohort study was conducted using United Kingdom primary care data. Patients with COPD aged ≥40 years with a history of smoking were included if they initiated TT or DB from no maintenance/LAMA therapy and had two or more exacerbations in the preceding year. The primary outcome was time to first COPD exacerbation. Secondary outcomes included time to treatment failure, first acute respiratory event, and first acute oral corticosteroid (OCS) course. Potential treatment effect modifiers were investigated. In 1647 matched patients, initiation of TT reduced exacerbation risk (adjusted hazard ratio (HR) 0.87, 95% CI 0.76–0.99), risk of acute respiratory event (HR 0.74, 95% CI 0.66–0.84) and treatment failure (HR 0.83, 95% CI 0.73–0.95) compared with DB. Risk reduction for acute respiratory events was greater for patients with higher rates of previous exacerbations. At baseline blood eosinophil counts (BECs) ≥ 0.35×109 cells·L−1, TT was associated with lower risk of OCS prescriptions than DB. This study provides real-life evidence of TT being more effective in reducing exacerbation risk than DB, which became more accentuated with increasing BEC and previous exacerbation rate.

Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort

2020 ◽  
Author(s):  
Heinrich Worth ◽  
Roland Buhl ◽  
Peter Kardos ◽  
Victoria Obermoser ◽  
Eva Gückel ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Baseline Data ◽  
Copd Patients ◽  
Dual Bronchodilation
Sign in / Sign up

Export Citation Format

Share Document